LETOU游戏中心网页版
公司简介
管理团队
愿景与使命
发展历程
联系我们
科学研究
抗生素耐药性
肾病靶向治疗
LETOU国际米兰研发模式
发表文献
研发管线
新闻中心
新闻发布
投资者关系
公司治理
临时公告
定期报告
投资者服务
股票信息
加入我们
联系我们
En
科学研究
以良药求良效。
首页
发表文献
抗生素耐药性
肾病靶向治疗
LETOU国际米兰研发模式
发表文献
Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens
Antimicrobial Agents and Chemotherapy / 2020
View Publication
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Antimicrob Agents Chemother / 2020
View Publication
Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
Antimicrob Agents Chemother / 2020
View Publication
Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent,in Chinese Patients
Clinical Therapeutics / 2020
View Publication
Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
Clinical Therapeutics / 2019
View Publication
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
J Pharmacokinet Pharmacodyn / 2019
View Publication
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Clinical Therapeutics / 2018
View Publication
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis
Antimicrob Agents Chemother / 2018
View Publication
Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
Antimicrob Agents Chemother / 2017
View Publication
Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes
Drug Metab Dispos / 2015
View Publication
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile
J Med Chem / 2014
View Publication
Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
Int J Antimicrob Agents / 2014
View Publication
<
1
2
3
>
关闭